Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal


Author index

Page Path
HOME > Browse > Author index
Mi-Hyun Kim  (Kim MH) 1 Article
The Incretins and Pancreatic β-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus
Mi-Hyun Kim, Moon-Kyu Lee
Korean Diabetes J. 2010;34(1):2-9.   Published online February 28, 2010
  • 4,427 View
  • 39 Download
  • 10 Crossref
AbstractAbstract PDFPubReader   

Type 2 diabetes mellitus (T2DM) is increasing in prevalence worldwide. The complications associated with T2DM result in increased mortality and financial cost for those affected. T2DM has long been known to be associated with insulin resistance in peripheral tissues and a relative degree of insulin deficiency. However, the concept that insulin secretion and insulin sensitivity are not linked through a hyperbolic relationship in T2DM has continuously been demonstrated in many clinical trials. Thus, in order to prevent and treat T2DM, it is necessary to identify the substance(s) that will improve the function and survival of the pancreatic β-cells in both normal and pathologic conditions, so that production and secretion of insulin can be enhanced. Incretin hormones, such as glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP), have been shown to lower the postprandial and fasting glucose and the glycated hemoglobin levels, suppress the elevated glucagon level, and stimulate glucose-dependent insulin synthesis and secretion. In this report, we will review the biological actions and mechanisms associated with the actions of incretin hormones, GLP-1 and GIP, on β-cell health and compare the differences between GLP-1 and GIP.


Citations to this article as recorded by  
  • A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects
    Xianglei Gao, Yujing Di, Yuan Lv, Yingcai Luan, Yang Xiong, Yuli Xu, Yusheng Li, Linfeng Guo, Xiaoping Li, Li Deng, Yulei Zhuang, Jie Hou
    Clinical and Translational Science.2024;[Epub]     CrossRef
  • A phase I study comparing the pharmacokinetics of the biosimilar (RD12014) with liraglutide (Victoza) in healthy Chinese male subjects
    Ruirui Zhou, Linfeng Guo, Xianglei Gao, Yijun Wang, Wenjing Xu, Yang Zou, Wenjia Li, Yulei Zhuang, Gangyi Liu, Yanmei Liu
    Clinical and Translational Science.2022; 15(10): 2458.     CrossRef
  • Misregulation of Wnt Signaling Pathways at the Plasma Membrane in Brain and Metabolic Diseases
    Mustafa Karabicici, Yagmur Azbazdar, Evin Iscan, Gunes Ozhan
    Membranes.2021; 11(11): 844.     CrossRef
  • Effects of newly introduced antidiabetic drugs on autophagy
    Milad Ashrafizadeh, Habib Yaribeygi, Stephen L. Atkin, Amirhossein Sahebkar
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(4): 2445.     CrossRef
  • Genistein enhances the secretion of glucagon-like peptide-1 (GLP-1) via downregulation of inflammatory responses
    Kanwal Rehman, Mehwish Bagh Ali, Muhammad Sajid Hamid Akash
    Biomedicine & Pharmacotherapy.2019; 112: 108670.     CrossRef
  • Liraglutide vs Exenatide: Patient Adherence, Medication Persistence and Economic Evaluation in the Treatment of Type 2 Diabetes Mellitus
    Fiorenzo Santoleri, Paola Sorice, Ruggero Lasala, Alberto Costantini
    Pharmacology & Pharmacy.2014; 05(04): 332.     CrossRef
  • Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling
    Mi-Hyun Kim, Jae-Hwan Jee, Sunyoung Park, Myung-Shik Lee, Kwang-Won Kim, Moon-Kyu Lee
    Journal of Endocrinology.2014; 220(2): 117.     CrossRef
  • Predicting the DPP-IV Inhibitory ActivitypIC50Based on Their Physicochemical Properties
    Tianhong Gu, Xiaoyan Yang, Minjie Li, Milin Wu, Qiang Su, Wencong Lu, Yuhui Zhang
    BioMed Research International.2013; 2013: 1.     CrossRef
  • Exendin-4 Protects Against Sulfonylurea-Induced β-Cell Apoptosis
    Ju-Young Kim, Dong-Mee Lim, Hyung-Seo Park, Chan-Il Moon, Kyung-Jin Choi, Seong-Kyu Lee, Haing-Woon Baik, Keun-Young Park, Byung-Joon Kim
    Journal of Pharmacological Sciences.2012; 118(1): 65.     CrossRef
  • Retrospective Analysis on the Efficacy, Safety and Treatment Failure Group of Sitagliptin for Mean 10-Month Duration
    Won Jun Kim, Cheol-Young Park, Eun Haeng Jeong, Jeong Youn Seo, Ji Soo Seol, Se Eun Park, Eun Jung Rhee, Won Young Lee, Ki Won Oh, Sung Woo Park, Sun Woo Kim
    Diabetes & Metabolism Journal.2011; 35(3): 290.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer